ADMA Biologics (ADMA) Competitors

Solid Biosciences (NASDAQ:SLDB) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Is SLDB or ADMA more profitable?

ADMA Biologics has a net margin of 17.80% compared to Solid Biosciences' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-58.75%	-47.84%
ADMA Biologics	17.80%	53.20%	26.07%

Does the media prefer SLDB or ADMA?

In the previous week, ADMA Biologics had 7 more articles in the media than Solid Biosciences. MarketBeat recorded 12 mentions for ADMA Biologics and 5 mentions for Solid Biosciences. ADMA Biologics' average media sentiment score of 0.49 beat Solid Biosciences' score of -0.40 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, SLDB or ADMA?

Solid Biosciences has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Which has higher earnings and valuation, SLDB or ADMA?

ADMA Biologics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	$8.09M	26.72	-$96.01M	-$3.04	-1.78
ADMA Biologics	$382.81M	13.08	-$28.24M	$0.28	75.64

Do analysts rate SLDB or ADMA?

Solid Biosciences presently has a consensus price target of $15.14, suggesting a potential upside of 179.90%. ADMA Biologics has a consensus price target of $21.25, suggesting a potential upside of 0.33%. Given Solid Biosciences' higher possible upside, equities analysts plainly believe Solid Biosciences is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the MarketBeat Community believe in SLDB or ADMA?

ADMA Biologics received 149 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 72.08% of users gave ADMA Biologics an outperform vote while only 68.39% of users gave Solid Biosciences an outperform vote.

Company	Underperform	Outperform
Solid Biosciences	Outperform Votes 264 68.39%	Underperform Votes 122 31.61%
ADMA Biologics	Outperform Votes 413 72.08%	Underperform Votes 160 27.92%

Do insiders & institutionals have more ownership in SLDB or ADMA?

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Solid Biosciences on 12 of the 19 factors compared between the two stocks.